Drug intelligence / Profile preview

AB410x

Development stage: Preclinical
Lead developer: AevisBio
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

AB410x is a molecular glue degrader (TPD) developed by AevisBio that targets Polo-like kinase 1 (PLK1). By inducing the degradation of PLK1, a key regulator of the cell cycle, AB410x aims to disrupt mitosis and induce apoptosis in cancer cells. The drug is currently in the lead optimization stage for the treatment of various malignancies, including acute myeloid leukemia (AML), multiple myeloma (MM), metastatic colorectal cancer (mCRC), and triple-negative breast cancer (TNBC).

Targets

CRBN (Cereblon)

Beyond the preview

Go deeper on AB410x.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB410x.

Explore the full profile